An inhibitor of SPHK2 (Ki 9 8 UM) inhibits SPHK2 (IC50 60 M) without affecting SPHK1 activity up to 100 M but does reduce SPHK1a protein levels in cells via an SPHK1-indirect proteasomal-dependent mechanism at 5-25 UM inactive against a panel of 20 lipid-regulated kinases at 50 M inhibits proliferation of a variety of human cancer cell lines (IC50s 6 12 2 32 8 and 48 1 UM respectively) reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma at 35 and 100 mg/kg every other day reduces colonic inflammation in mouse and rat models of Crohn s disease